Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N
1 Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
2 Clinical Immunology, Angioedema and Allergy Unit, The Zabludowicz Center for Autoimmune Diseases, 26744 Sheba Medical Center, Tel Hashomer , Israel.
Lupus. 2018 Apr;27(5):703-707. doi: 10.1177/0961203317735185. Epub 2017 Oct 9.
Hydroxychloroquine (HCQ) is widely used to treat autoimmune/rheumatic diseases such as systemic lupus erythematosus (SLE). The immune modulation effects of HCQ have been highlighted as beneficial for maintaining remission of SLE as well as ameliorating skin, joint and other manifestations. Moreover, HCQ exposure for prolonged periods as well as during pregnancy is considered safe, therefore it is recommended for the vast majority of SLE patients. Although HCQ therapy requires follow-up by a specialist, its most common side effects are mild gastrointestinal disturbances, sensitivity to light and skin rashes. Of these side effects, hypersensitivity skin reactions have been suggested to play a role in reduced compliance to HCQ therapy. In the current study we present a two-stage HCQ desensitization protocol that was successfully implemented among 12 out of 13 patients. We exhibit that prolonged HCQ oral desensitization is an effective method for overcoming mild to moderate late hypersensitivity reactions and thoroughly address possible mechanisms of action.
羟氯喹(HCQ)被广泛用于治疗自身免疫性/风湿性疾病,如系统性红斑狼疮(SLE)。HCQ的免疫调节作用已被视为有助于维持SLE的缓解以及改善皮肤、关节和其他症状。此外,长期以及孕期使用HCQ被认为是安全的,因此推荐给绝大多数SLE患者。虽然HCQ治疗需要专科医生随访,但其最常见的副作用是轻度胃肠道不适、对光敏感和皮疹。在这些副作用中,皮肤过敏反应被认为会导致患者对HCQ治疗的依从性降低。在本研究中,我们提出了一种两阶段的HCQ脱敏方案,该方案在13例患者中的12例中成功实施。我们证明,长期口服HCQ脱敏是克服轻至中度迟发性过敏反应的有效方法,并深入探讨了可能的作用机制。